Get notified when TNON files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRisk Profile Improvements
- Going Concern (unchanged) — Company continues to disclose substantial doubt about ability to continue as going concern due to insufficient cash for next 12 months.
- Material Weakness (unchanged) — Internal control material weakness persists due to inadequate segregation of duties from limited resources.
Tenon Medical revenue doubles on new product, but cash burn persists with going concern
Filed May 15, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 13, 2025 · ~1 min read
Key Changes
-
high
Revenue jumped 90% YoY to $1.4M driven by SImmetry+ acquisition and higher procedure volume; gross margin improved from 44% to 69% on better overhead absorption.
MD&A: Revenue and Gross Margin verify on EDGAR → -
high
Cash declined 55% to $4.6M despite revenue growth; company issued convertible notes generating $3.9M and maintains going-concern disclosure citing insufficient liquidity for next 12 months.
MD&A: Liquidity and Financing verify on EDGAR → -
high
Acquired SImmetry+ SI Joint fusion system in August 2025, diversifying product portfolio beyond original Catamaran System and contributing to Q1 2026 revenue.
MD&A: SImmetry+ Acquisition verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (SNOA 10-K) is open in full — no account needed.
Partner
Trade TNON commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · May 25, 2026 5:40 AM